Member Info for Chelsea11

It’s only dial-up internet in those cardboard labs

Not impossible there will be some positive news ahead of 23/06 - contract win etc.

Link below is interesting. No mention of Scancell but does illustrate the drive in this area of medicine (and who knows who is collaborating with whom).

https://www.wfmz.com/news/pr_newswire/pr_newswire_health/global-cancer-vaccine-platforms-markets-report-2022-use-of-new-drugs-in-combination-with-antigen/article_f8f917e1-4067-5bb7-b013-305c3df3b15c.html

You won’t be able to view the actual report published at researchandmarkets unless you’re prepared to pay.

C7 - KTBFFH!

Enjoy.

TF re your 11:09, I wasn’t inferring that you were.

HAGW

In all fairness and for balance, I’d rather have a news void than a procession of RNS that are weak in content, at best. We can all think of other shares where “news” is pushed out just for the sake of it, sometimes of a laughable nature and smacks of desperation.

Better not to be viewed like that imo.

Take it easy all. Holding strong :-)

Need something, otherwise Sid the Sixpence will come in from the cold :-)

Highly satisfactory Trading Update imo, in turbulent markets. Safe haven, again imo.

Why no Notice of Results??

Forgot to mention, it’s worth having a look at the Media Gallery for the Event. I suspect all photos / videos from prior years but even so, provide a flavour of what Scancell have been part of yesterday.

https://www.pegsummit.com/media-gallery

Remember there was a Scancell speaker on the Agenda yesterday afternoon at PEGS Boston.

Mireille Vankemmelbeke, PhD, Principal Scientist, Biodiscovery, Scancell Ltd
Glycans are excellent tumor targets. Notably, the same glycan expressed on a range of glycoproteins/lipids allows mAbs to target multiple antigens some of which can internalize whilst others are retained on the cell surface. Our mAbs can be potent ADCs but also retain ADCC/CDC activity and can cause membrane perturbation resulting in direct cell lysis. Additionally, Avidimab increases the avidity of any mAb and results in improved tumor killing.

We also believe Lindy was in attendance and so networking opportunities galore I hope! As Burble endorsed, PEGS is huge.

Fingers crossed for a blue day ahead.

Matt - I can confirm it will be anytime :-)

I was wondering about Modi FPD and whether this could be persons (plural), rather than a single person. That would add some weight to an FPD RNS but don’t know how likely that is given safety considerations etc.

Ah I see you did that - apols!

Good weekend all.

Click on “Last edited x hours ago (in green) near the bottom of the page and you can see the editing history.

For anyone thinking they might like a page of their own. Some of course may be “notable” enough to have one already!

https://en.wikipedia.org/wiki/Wikipedia:Notability

WTP - yeah v interesting and thanks. Seems the Page was only created yesterday and so not sure of the significance of that timing? Loving all the References at the foot of the page.

WTP - when I put the first post up on this, it was by speaker, not attendee, so suspect Lindy was in the attendee list all along.

PEGS Boston Conference 2nd-6th May.

Scancell speaker on 5th May:

Mireille Vankemmelbeke, PhD, Principal Scientist, Biodiscovery, Scancell Ltd
Glycans are excellent tumor targets. Notably, the same glycan expressed on a range of glycoproteins/lipids allows mAbs to target multiple antigens some of which can internalize whilst others are retained on the cell surface. Our mAbs can be potent ADCs but also retain ADCC/CDC activity and can cause membrane perturbation resulting in direct cell lysis. Additionally, Avidimab increases the avidity of any mAb and results in improved tumor killing.

https://www.pegsummit.com/

Menu - Agenda - Speaker Biographies - Search Scancell

I’ve dropped the National Geo Reporter a message, asking if she is aware of Scancell / Covidity.

Soon be a whole year since Zakari was incorporated. Did anyone ever uncover the mystery?

https://find-and-update.company-information.service.gov.uk/company/13408042